Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

Authors Bennett JW, Lewis II JS, Ellis MW

Published 8 February 2008 Volume 2008:4(1) Pages 31—40


Jason W Bennett1, James S Lewis II2, Michael W Ellis1

1Department of Medicine-Infectious Disease Service, Brooke Army Medical Center, Fort Sam Houston, TX, USA; 2Department of Medicine-Division of Infectious Diseases, University of Texas Health Science Center, San Antonio, TX, USA

Abstract: Increasing rates of antimicrobial resistance among strains of Streptococcus, Staphylococcus, and Enterococcus spp. have been widely documented. At least 50% of nosocomial Staphylococcus aureus infections in intensive care units in the US and UK are due methicillin-resistant S. aureus (MRSA). Drug resistance is not confined to hospitals, and community-acquired MRSA (CA-MRSA) strains are now common causes of complicated skin and soft-tissue infections (cSSTIs) in many regions. Dalbavancin is a novel parenterally administered semisynthetic lipoglycopeptide similar to the naturally produced glycopeptides vancomycin and teicoplanin. Dalbavancin features a multifaceted mechanism of action that inhibits bacterial cell wall formation by two different mechanisms that enhances its activity against a wide range of gram-positive bacteria including staphylococci, streptococci, enterococci, and some anaerobes. Additionally, dalbavancin possesses unique pharmacokinetic properties, the most significant of which is a long terminal half-life that allows for once weekly dosing. This attribute may prove to yield clinical and cost benefit. Overall, clinical trials indicate that dalbavancin is a safe, well-tolerated, and effective antimicrobial agent. In the largest investigation evaluating dalbavancin for the treatment of cSSTIs, it appeared to be as effective as linezolid. Dalbavancin, which is expected to receive FDA approval in 2008, appears to be a promising new antimicrobial agent for the treatment of cSSTIs.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

Marslin G, Revina AM, Khandelwal VKM, Balakumar K, Prakash J, Franklin G, Sheeba CJ

International Journal of Nanomedicine 2015, 10:3163-3170

Published Date: 24 April 2015

Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice

Liu Z, Li J, Li J, Huang J, Ke F, Qi Q, Jiang X, Zhong Z

International Journal of Nanomedicine 2012, 7:5039-5049

Published Date: 17 September 2012

Lift the quilt in case of atrial fibrillation and disc prolapse

Bastovansky A, Ziegler K, Stöllberger C, Finsterer J

Vascular Health and Risk Management 2012, 8:389-392

Published Date: 22 June 2012

Spectral domain OCT versus time domain OCT in the evaluation of macular features related to wet age-related macular degeneration

Pierro L, Zampedri E, Milani P, Gagliardi M, Isola V, Pece A

Clinical Ophthalmology 2012, 6:219-223

Published Date: 9 February 2012

Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy

Mischel G Neill, Rohan Shahani, Alexandre R Zlotta

Therapeutics and Clinical Risk Management 2008, 4:11-18

Published Date: 8 February 2008

Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris

Efstratios Vakirlis, Athanasios Kastanis, Demetrios Ioannides

Therapeutics and Clinical Risk Management 2008, 4:141-148

Published Date: 8 February 2008

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting

Mark A Ware, Paul Daeninck, Vincent Maida

Therapeutics and Clinical Risk Management 2008, 4:99-107

Published Date: 8 February 2008

Treating oligohydramnios with extract of Salvia miltiorrhiza: A randomized control trial

Hong-nü Chu, Mei-juan Shen

Therapeutics and Clinical Risk Management 2008, 4:287-290

Published Date: 8 February 2008

Cannabinoids in the management of difficult to treat pain

Ethan B Russo

Therapeutics and Clinical Risk Management 2008, 4:245-259

Published Date: 8 February 2008